JP2022518441A5 - - Google Patents

Info

Publication number
JP2022518441A5
JP2022518441A5 JP2021541095A JP2021541095A JP2022518441A5 JP 2022518441 A5 JP2022518441 A5 JP 2022518441A5 JP 2021541095 A JP2021541095 A JP 2021541095A JP 2021541095 A JP2021541095 A JP 2021541095A JP 2022518441 A5 JP2022518441 A5 JP 2022518441A5
Authority
JP
Japan
Prior art keywords
seq
formulation according
formulation
heavy chain
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021541095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518441A (ja
JP7539897B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013916 external-priority patent/WO2020150496A1/en
Publication of JP2022518441A publication Critical patent/JP2022518441A/ja
Publication of JP2022518441A5 publication Critical patent/JP2022518441A5/ja
Application granted granted Critical
Publication of JP7539897B2 publication Critical patent/JP7539897B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021541095A 2019-01-16 2020-01-16 ヒトcd137に結合する抗体の製剤およびその使用 Active JP7539897B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962793342P 2019-01-16 2019-01-16
US62/793,342 2019-01-16
US202062960501P 2020-01-13 2020-01-13
US62/960,501 2020-01-13
PCT/US2020/013916 WO2020150496A1 (en) 2019-01-16 2020-01-16 Formulations of antibodies that bind human cd137 and uses thereof

Publications (3)

Publication Number Publication Date
JP2022518441A JP2022518441A (ja) 2022-03-15
JP2022518441A5 true JP2022518441A5 (https=) 2023-01-20
JP7539897B2 JP7539897B2 (ja) 2024-08-26

Family

ID=69724049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541095A Active JP7539897B2 (ja) 2019-01-16 2020-01-16 ヒトcd137に結合する抗体の製剤およびその使用

Country Status (12)

Country Link
US (1) US20220111047A1 (https=)
EP (1) EP3911679A1 (https=)
JP (1) JP7539897B2 (https=)
KR (1) KR20210131312A (https=)
CN (1) CN113474371B (https=)
AU (1) AU2020208397A1 (https=)
BR (1) BR112021013571A2 (https=)
CA (1) CA3127072A1 (https=)
IL (1) IL284208A (https=)
MX (1) MX2021008453A (https=)
SG (1) SG11202107538VA (https=)
WO (1) WO2020150496A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022178114A1 (en) * 2021-02-17 2022-08-25 Aptevo Research And Development Llc Compositions comprising 4-1bb and ox40 binding proteins and methods of use
CN118090983B (zh) * 2024-04-26 2024-09-06 山东齐都药业有限公司 布比卡因/美洛昔康复方凝胶中活性物质的检测方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
CA2765220A1 (en) * 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
SG181533A1 (en) * 2009-12-07 2012-07-30 Univ Leland Stanford Junior Methods for enhancing anti-tumor antibody therapy
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
MX337040B (es) * 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
JP6845846B6 (ja) * 2015-09-22 2021-04-21 ディンフー バイオターゲット カンパニー リミテッド 抗ヒトcd137の完全ヒト抗体及びその用途
AU2018301393B2 (en) * 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
WO2019089753A2 (en) * 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof

Similar Documents

Publication Publication Date Title
US20260115254A1 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
CN109912683B (zh) 一种细胞毒素分子、偶联物及其制备方法和应用
US11873281B2 (en) Conjugates of cell binding molecules with cytotoxic agents
US20260091081A1 (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
TWI440470B (zh) 含改良抗體分子之醫藥配方
US7939074B2 (en) Combination of an anti-EP-CAM antibody with a chemotherapeutic agent
RU2633509C2 (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
JP2021517129A5 (https=)
IL275274B1 (en) Conjugation of a tubulin analog with branched linkers
JP2001518930A (ja) 抗cd−22抗体を使用したb細胞悪性疾患の免疫療法
JP2017524693A (ja) 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
CN111050791A (zh) 用于抗tim-3抗体的给药方案及其用途
JP2013500947A5 (https=)
CN107252485A (zh) 用于诱导对疾病的免疫应答的组合疗法
JP2022507606A (ja) Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
JP2024506940A5 (https=)
JP2022518441A5 (https=)
AR129062A1 (es) Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
KR20210039395A (ko) 마스킹된 항체의 약제학적 제형
JP2025504419A5 (https=)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
TW202120550A (zh) 雙特異性蛋白質
CN111683681A (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
JP2024505128A5 (https=)
CN118767126A (zh) 抗cd47抗体和阿扎胞苷联合治疗血液肿瘤